(0.19%) 5 141.50 points
(0.13%) 38 490 points
(0.31%) 17 901 points
(-0.44%) $83.48
(1.61%) $1.954
(0.12%) $2 350.00
(0.39%) $27.64
(1.24%) $933.50
(-0.01%) $0.935
(-0.13%) $11.01
(-0.12%) $0.799
(1.29%) $93.06
Live Chart Being Loaded With Signals
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases...
Stats | |
---|---|
本日の出来高 | 2.93M |
平均出来高 | 3.52M |
時価総額 | 6.76B |
EPS | HKD0 ( 2022-03-22 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -11.27 |
ATR14 | HKD0.00500 (0.11%) |
ボリューム 相関
InnoCare Pharma Ltd 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
InnoCare Pharma Ltd 相関 - 通貨/商品
InnoCare Pharma Ltd 財務諸表
Annual | 2023 |
収益: | HKD738.54M |
総利益: | HKD610.10M (82.61 %) |
EPS: | HKD-0.370 |
FY | 2023 |
収益: | HKD738.54M |
総利益: | HKD610.10M (82.61 %) |
EPS: | HKD-0.370 |
FY | 2022 |
収益: | HKD625.40M |
総利益: | HKD482.01M (77.07 %) |
EPS: | HKD-0.590 |
FY | 2021 |
収益: | HKD1.04B |
総利益: | HKD977.37M (93.70 %) |
EPS: | HKD-0.0500 |
Financial Reports:
No articles found.
InnoCare Pharma Ltd
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。